With all of the stock picks and recommendations available today, selecting and deciding on the right stocks can be tedious and time consuming. At QualityStocks, we collate hundreds of investment newsletters into The ONE and ONLY “The QualityStocks Daily”, featuring a summary format in which you can view the latest stock picks.
Our newsletter provides the latest coverage in the Small-Cap and Micro-Cap markets, providing you with a ONE-STOP information resource. The QualityStocks Daily helps subscribers stay on top of momentum trading opportunities, discover high performance winning stock picks, track the performance of hundreds of stock newsletters and learn about new investment newsletter sources as they are published!
To sign up for the QualityStocks Newsletter, visit www.Signup.QualityStocks.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, October 2, 2012
CytRx Corp. (CYTR) Presents Clinical Findings for Aldoxorubicin Trial at ESMO 2012 Congress
CytRx, a biopharmaceutical company that specializes in oncology, yesterday announced favorable data from its Phase 1b/2 clinical trial of its doxorubicin conjugate aldoxorubicin (previously INNO-206), a treatment designed to target and combat tumors. The favorable results from its trial in patients with an advanced form of soft tissue sarcoma was presented at the Sarcoma Poster-Discussion Session (Hall H) at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria. Renowned sarcoma specialist, Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, CA, led the presentation, entitled “INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue Sarcoma.”
The aldoxorubicin Phase 1b/2 clinical trial data showed “clinical benefit” (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) for those patients that received the maximum tolerated dose of aldoxorubicin. Of evaluable patients, all of whom suffer from relapsed or refractory soft tissue sarcoma, 10 in 13 (77%) exhibited signs of clinical benefit. The first of this data was presented on June 3, 2012, at the ASCO (American Society of Clinical Oncology) Conference.
Steven A. Kriegsman, CEO and President of CytRx said, “These clinical trial results with aldoxorubicin were introduced at ASCO, presented today at ESMO, and will be featured at the Connective Tissue Oncology Society (CTOS) Conference in Prague, Czech Republic, in November. We believe that the avid reception for presentation of the aldoxorubicin clinical data by leading oncology conferences is a testament to their importance and we are pleased that these clinical results are capturing the attention of the oncology community.”
“Although the trial data are derived from a small patient group, the fact that clinical benefit was seen in 77% of these patients is noteworthy, particularly given the advanced stage of disease,” said the clinical trial’s principal investigator and renowned sarcoma expert Sant P. Chawla, M.D., F.R.A.C.P. “Further, of the eight evaluable patients who were previously treated with doxorubicin and had either not responded or relapsed, five showed clinical benefit with aldoxorubicin. Among these, three showed prolonged partial responses with greater than 30% tumor shrinkage.”
Aldoxorubicin works by combining doxorubicin, a commonly used chemotherapeutic agent, with a proprietary linker technology. Because doxorubicin has an inherent toxicity level, patients are limited to specific doses to protect them from overexposure. However, because the linker technology delivers doxorubicin to tumor sites (where the delivery molecule is cleaved and the doxorubicin is released), the potential exists to increase the drug’s efficacy, while avoiding many of the associated side effects.
CytRx Corporation has plans to meet with the FDA during the second half of 2012 to discuss a potential Phase 3 pivotal trial for patients who have since relapsed or were refractory to chemotherapy.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The aldoxorubicin Phase 1b/2 clinical trial data showed “clinical benefit” (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) for those patients that received the maximum tolerated dose of aldoxorubicin. Of evaluable patients, all of whom suffer from relapsed or refractory soft tissue sarcoma, 10 in 13 (77%) exhibited signs of clinical benefit. The first of this data was presented on June 3, 2012, at the ASCO (American Society of Clinical Oncology) Conference.
Steven A. Kriegsman, CEO and President of CytRx said, “These clinical trial results with aldoxorubicin were introduced at ASCO, presented today at ESMO, and will be featured at the Connective Tissue Oncology Society (CTOS) Conference in Prague, Czech Republic, in November. We believe that the avid reception for presentation of the aldoxorubicin clinical data by leading oncology conferences is a testament to their importance and we are pleased that these clinical results are capturing the attention of the oncology community.”
“Although the trial data are derived from a small patient group, the fact that clinical benefit was seen in 77% of these patients is noteworthy, particularly given the advanced stage of disease,” said the clinical trial’s principal investigator and renowned sarcoma expert Sant P. Chawla, M.D., F.R.A.C.P. “Further, of the eight evaluable patients who were previously treated with doxorubicin and had either not responded or relapsed, five showed clinical benefit with aldoxorubicin. Among these, three showed prolonged partial responses with greater than 30% tumor shrinkage.”
Aldoxorubicin works by combining doxorubicin, a commonly used chemotherapeutic agent, with a proprietary linker technology. Because doxorubicin has an inherent toxicity level, patients are limited to specific doses to protect them from overexposure. However, because the linker technology delivers doxorubicin to tumor sites (where the delivery molecule is cleaved and the doxorubicin is released), the potential exists to increase the drug’s efficacy, while avoiding many of the associated side effects.
CytRx Corporation has plans to meet with the FDA during the second half of 2012 to discuss a potential Phase 3 pivotal trial for patients who have since relapsed or were refractory to chemotherapy.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, October 1, 2012
Clean Wind Energy Tower, Inc. (CWET) Signs LOI to Purchase Energy Project Site in Mexico
Clean Wind Energy Tower has entered into a letter of intent (LOI) to buy a 3,200-acre site in Mexico that is complementary to the company’s alternative energy project currently under development.
The company plans to build and operate two Clean Wind Energy Downdraft Towers on the site, which the company says offers suitable access and ideal topography, making the location a “particularly exceptional area.”
“We are excited about the opportunity to locate two Downdraft Towers in this region as it is one of the prime locations in the world due to the climate, which enables the Tower to produce an optimum amount of clean, renewable energy,” Ronald W. Pickett, Clean Wind’s chairman and CEO stated in the press release.
Pickett noted that other ideal locations include areas in Western Australia, North Africa, and select regions of South America, India, the Middle East, and South West USA.
Clean Wind and the current land owner began discussions regarding this project in late 2011, and have since collaborated under the LOI toward reaching a definitive agreement.
For more information visit www.cleanwindenergytower.com/tower.html#demo
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The company plans to build and operate two Clean Wind Energy Downdraft Towers on the site, which the company says offers suitable access and ideal topography, making the location a “particularly exceptional area.”
“We are excited about the opportunity to locate two Downdraft Towers in this region as it is one of the prime locations in the world due to the climate, which enables the Tower to produce an optimum amount of clean, renewable energy,” Ronald W. Pickett, Clean Wind’s chairman and CEO stated in the press release.
Pickett noted that other ideal locations include areas in Western Australia, North Africa, and select regions of South America, India, the Middle East, and South West USA.
Clean Wind and the current land owner began discussions regarding this project in late 2011, and have since collaborated under the LOI toward reaching a definitive agreement.
For more information visit www.cleanwindenergytower.com/tower.html#demo
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Comstock Mining, Inc. (LODE) Celebrates First Gold and Silver Pour, Announces Commemorative Pieces
Comstock Mining, Inc. (LODE) Celebrates First Gold and Silver Pour, Announces Commemorative Pieces
Comstock Mining has built up a nice, big, contiguous acreage footprint in Nevada’s Comstock District and now holds the single largest known repository of historical and current geological data on the district in addition to their consolidated land position, making today’s announcement that the company poured their first gold and silver dore bars, totaling some 3,743 ounces smelted from Merrill Crowe precipitate, a real moment for shareholders to be proud of.
This milestone pour signifies a triumphant conclusion to the LODE “March to Production” project, and with the sale of the metal for over $700k ($1,777.25/oz Au and $34.61/oz Ag), a solid revenue stream has been established. Bar assay shows 88.2% Ag with 8.5% gold content and this first spate of pours has thus output some 329 oz Au, with another 3,414 oz of silver.
It’s great to see an entire on-site closed loop that goes from mining and hauling all the way through to pouring some metal. At this point the company is merely refining throughput optimization, going to each phase of the crushing, stacking, leaching, processing, filtering, drying, and etc. with an eye to statistical process control implementation. Further refinement of the dore bar for gold and silver bullion is to be handled at a contracted refinery.
In celebration of this momentous occasion, Comstock Mining has held back one dore bar to strike a limited, sequentially numbered run of commemorative one-troy-ounce pieces with a 10 to 1, Ag to Au content, on a first come, first serve basis.
President and CEO of LODE, Corrado DeGasperis, hailed the mining community and stakeholders for their continued support, clearly proud of the company’s steadfast march that has led up to the completion of these first pours, confidently proclaiming that safe, efficient, responsible mining has returned to the legendary Comstock. Not only does this historic achievement signify the herculean effort by the company’s Nevada team, putting together such a huge land package and the associated analytical knowledge/facilities required to turn it into a fully producing operation, but also that which is struck into the commemorative pieces themselves, a sense of America’s return to its roots, pressed into precious metal that was taken directly out of the heart of the Comstock itself.
DeGasperis noted that with this milestone achieved, the company would be turning its primary focus toward maximizing and sustaining throughput from the Lucerne Resource Area mine, with the goal of getting the figure well over the current 1M dry tons per year. This will offer considerable breathing room for the company’s operations, as an annual output rate of 20k gold-equivalent ounces and stabilized cash flow enables LODE to look more closely at expanding production levels even further with the approach of 2013. Precious metals are following a very clear trend underwritten further by open-ended quantitative easing, and producers like LODE will be able to chase that curve with what looks like increasing margins, taking shareholders along for the profit ride. Investors are increasingly turning towards the mining sector as a fundamentals-based hedge. Exceptionally propitious timing for Comstock really, reporting their first pour as gold landed its biggest quarterly gain in two years Friday, rallying around QE infinity and a variety of contracting fundamental indicators out of China and Europe.
The company is eagerly acquiring additional prime territory in the district and has set a strategic goal of 3.2M gold-equivalent ounces (measured and indicated or probable and proven) for 2013, in addition to the 20k gold-equivalent ounce annual production rate.
For more information on Comstock Mining, please visit the company’s website at: www.ComstockMining.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Comstock Mining has built up a nice, big, contiguous acreage footprint in Nevada’s Comstock District and now holds the single largest known repository of historical and current geological data on the district in addition to their consolidated land position, making today’s announcement that the company poured their first gold and silver dore bars, totaling some 3,743 ounces smelted from Merrill Crowe precipitate, a real moment for shareholders to be proud of.
This milestone pour signifies a triumphant conclusion to the LODE “March to Production” project, and with the sale of the metal for over $700k ($1,777.25/oz Au and $34.61/oz Ag), a solid revenue stream has been established. Bar assay shows 88.2% Ag with 8.5% gold content and this first spate of pours has thus output some 329 oz Au, with another 3,414 oz of silver.
It’s great to see an entire on-site closed loop that goes from mining and hauling all the way through to pouring some metal. At this point the company is merely refining throughput optimization, going to each phase of the crushing, stacking, leaching, processing, filtering, drying, and etc. with an eye to statistical process control implementation. Further refinement of the dore bar for gold and silver bullion is to be handled at a contracted refinery.
In celebration of this momentous occasion, Comstock Mining has held back one dore bar to strike a limited, sequentially numbered run of commemorative one-troy-ounce pieces with a 10 to 1, Ag to Au content, on a first come, first serve basis.
President and CEO of LODE, Corrado DeGasperis, hailed the mining community and stakeholders for their continued support, clearly proud of the company’s steadfast march that has led up to the completion of these first pours, confidently proclaiming that safe, efficient, responsible mining has returned to the legendary Comstock. Not only does this historic achievement signify the herculean effort by the company’s Nevada team, putting together such a huge land package and the associated analytical knowledge/facilities required to turn it into a fully producing operation, but also that which is struck into the commemorative pieces themselves, a sense of America’s return to its roots, pressed into precious metal that was taken directly out of the heart of the Comstock itself.
DeGasperis noted that with this milestone achieved, the company would be turning its primary focus toward maximizing and sustaining throughput from the Lucerne Resource Area mine, with the goal of getting the figure well over the current 1M dry tons per year. This will offer considerable breathing room for the company’s operations, as an annual output rate of 20k gold-equivalent ounces and stabilized cash flow enables LODE to look more closely at expanding production levels even further with the approach of 2013. Precious metals are following a very clear trend underwritten further by open-ended quantitative easing, and producers like LODE will be able to chase that curve with what looks like increasing margins, taking shareholders along for the profit ride. Investors are increasingly turning towards the mining sector as a fundamentals-based hedge. Exceptionally propitious timing for Comstock really, reporting their first pour as gold landed its biggest quarterly gain in two years Friday, rallying around QE infinity and a variety of contracting fundamental indicators out of China and Europe.
The company is eagerly acquiring additional prime territory in the district and has set a strategic goal of 3.2M gold-equivalent ounces (measured and indicated or probable and proven) for 2013, in addition to the 20k gold-equivalent ounce annual production rate.
For more information on Comstock Mining, please visit the company’s website at: www.ComstockMining.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
AtheroNova, Inc. (AHRO) is “One to Watch”
AtheroNova is a promising development stage biotech firm that grew up in California (Corporate HQ still in Irvine) and is now engaged, via wholly owned subsidiary AtheroNova Operations, in advancing a portfolio of pharmacological compounds. The company is currently focused on their lead offering AHRO-001, a powerful technological breakthrough in combating atherosclerotic plaque and safely improving overall lipid profiles.
We are talking about a breakthrough in a field that is today dominated by statin drugs and other, largely ineffectual lipid regulators or treatments, with the total market space encompassing everything from imaging and diagnostic catheterizations, to drug eluting stents and the like. Statins are really pretty ineffective at current dosage levels (more is dangerous) for reducing the buildup of plaques and yet they are also the most effective method on the market today for delimiting serum cholesterol levels and raked in some $37B in 2010 alone. Statins also have terrible long-term usage safety metrics and carry significant drawbacks in terms of basic tolerability, meaning that a pharmaceutical based on the AHRO-001 compound, which is from a class of compounds that have a demonstrably long history of safety and regulatory approval in humans, could be a real breakout innovation that impacts across the entire field. The ability to deliver the compound in a variety of ways, from parenteral, oral, and transdermal, to in-loco, also offers exceptional implementation dynamics that allow the drug more ubiquitous market access.
Atherosclerosis, or (mostly) cholesterol plaque buildup/hardening on the walls of arteries, hits big, with 90% of U.S. adults having over 10% blockage. Cardiovascular disease affects 1 in 3 Americans today. That’s 85M people whose only options are ineffective statins, or really difficult to deal with stents, catheterization, and balloon angioplasties that don’t even reduce the amount of plaque. There were 8M peripheral artery disease patients in the U.S. in 2011 alone (33% diabetics), another 7M stroke patients, 18M men suffering from erectile dysfunction, and 6M more suffering from Dementia and Alzheimer’s. These numbers are staggering and account collectively for some 260M lipid-regulating drug prescriptions last year.
AtheroNova’s key IP comes from the founding work by Dr. Giorgio Zadini and Dr. Filiberto Zadini, co-inventors whose work is now shielded by the U.S. Patent and Trademark Office, which issued a Notice of Allowance for one of AHRO’s main patent applications (July 9), covering the AHRO-001 compound’s proprietary method for treating Atherosclerosis with a bile acid (naturally occurring bile acid, hyodeoxycholic acid, or HDCA). Basically we have a compound here that utilizes an established, safe vector for delipidizing the artery wall very rapidly by permeating the atherosclerotic fibrous cap and dissolving the composite material. In addition to widening the artery, this method averts rupturing/dislodging of plaque chunks that can lead to serious cardiac events, and AHRO also believes that further work will show that the delipidized artery walls will experience significant restoration of initial integrity as inflammation subsidizes.
AtheroNova is in the pole position moving forward for regression/stabilization of plaque through this technology and is well-positioned to capture significant space in with what is potentially going to become the gold standard for treatment in the sector. The licensing agreement signed in late 2011 with major Russian biotech fund, the Maxwell Biotech Group’s wholly-owned subsidiary, OOO CardioNova, to cover not only funding for Phase I-II human clinical trials in Russia, but also eventuating in direct market access to the massive Russian Federation, Ukraine, and various central Asian countries covered by the agreement, is a sweet deal for AHRO shareholders. The USPTO approval, alongside the Phase I-II clinical trialing campaign, adds serious weight to the recent success of preclinical study work completed in conjunction with UCLA and Cedars-Sinai, set to be published in the respective scientific journals (later this year by UCLA and in early 2013 by Cedars-Sinai). The CardioNova deal alone should result in impressive quarterly royalties on net sales over the full lifespan of the IP in that massive market and the global impact of a true statin alternative that also actually gets the job done safely should be enough to pique the interest of potential investors.
This technology also has abundant potential to strike out into new territory, with delipidization of subcutaneous fat being a primary target the company has developed IP for. This function has already been identified by research at top U.S. academic institutions in one of the compounds AHRO has determined to be effective and the potential for burning fat via localized transdermal delivery has, to say the least, exciting profit potential. It is important to stress the overall viability of delipidization and its effect on health and well-being. Given the safety of the compound and its effectiveness, we could be looking at the emergence of new general indication for delimiting lipid buildup throughout the body’s vast network of small peripheral vessels.
Presentations at the recent 2012 Aegis Capital Healthcare Conference (Sept 28) and Rodman & Renshaw 14th Annual Healthcare Conference (Sept 11), have left a lasting impression on the sector, with the incredible near-term potential of the leading AHRO-001 compound, the UCLA study data, and the company’s strong development pipeline all making a significant impact. The company is poised to validate the extant, very encouraging preclinical data with human clinical trials. The compound potential reaches across entire market segments and the absence of negative toxicological effects in the preclinical work accentuates the historically validated safety of this compound class in humans. AHRO-001 should be in Phase I by Q4 2012 and early next year we should see AHRO meeting again with FDA, as they did back in 2011, to clear the way for Phase II work and a U.S. IND filing.
For more information on this exciting young biotech firm, please visit the company’s website located at: www.AtheroNova.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
We are talking about a breakthrough in a field that is today dominated by statin drugs and other, largely ineffectual lipid regulators or treatments, with the total market space encompassing everything from imaging and diagnostic catheterizations, to drug eluting stents and the like. Statins are really pretty ineffective at current dosage levels (more is dangerous) for reducing the buildup of plaques and yet they are also the most effective method on the market today for delimiting serum cholesterol levels and raked in some $37B in 2010 alone. Statins also have terrible long-term usage safety metrics and carry significant drawbacks in terms of basic tolerability, meaning that a pharmaceutical based on the AHRO-001 compound, which is from a class of compounds that have a demonstrably long history of safety and regulatory approval in humans, could be a real breakout innovation that impacts across the entire field. The ability to deliver the compound in a variety of ways, from parenteral, oral, and transdermal, to in-loco, also offers exceptional implementation dynamics that allow the drug more ubiquitous market access.
Atherosclerosis, or (mostly) cholesterol plaque buildup/hardening on the walls of arteries, hits big, with 90% of U.S. adults having over 10% blockage. Cardiovascular disease affects 1 in 3 Americans today. That’s 85M people whose only options are ineffective statins, or really difficult to deal with stents, catheterization, and balloon angioplasties that don’t even reduce the amount of plaque. There were 8M peripheral artery disease patients in the U.S. in 2011 alone (33% diabetics), another 7M stroke patients, 18M men suffering from erectile dysfunction, and 6M more suffering from Dementia and Alzheimer’s. These numbers are staggering and account collectively for some 260M lipid-regulating drug prescriptions last year.
AtheroNova’s key IP comes from the founding work by Dr. Giorgio Zadini and Dr. Filiberto Zadini, co-inventors whose work is now shielded by the U.S. Patent and Trademark Office, which issued a Notice of Allowance for one of AHRO’s main patent applications (July 9), covering the AHRO-001 compound’s proprietary method for treating Atherosclerosis with a bile acid (naturally occurring bile acid, hyodeoxycholic acid, or HDCA). Basically we have a compound here that utilizes an established, safe vector for delipidizing the artery wall very rapidly by permeating the atherosclerotic fibrous cap and dissolving the composite material. In addition to widening the artery, this method averts rupturing/dislodging of plaque chunks that can lead to serious cardiac events, and AHRO also believes that further work will show that the delipidized artery walls will experience significant restoration of initial integrity as inflammation subsidizes.
AtheroNova is in the pole position moving forward for regression/stabilization of plaque through this technology and is well-positioned to capture significant space in with what is potentially going to become the gold standard for treatment in the sector. The licensing agreement signed in late 2011 with major Russian biotech fund, the Maxwell Biotech Group’s wholly-owned subsidiary, OOO CardioNova, to cover not only funding for Phase I-II human clinical trials in Russia, but also eventuating in direct market access to the massive Russian Federation, Ukraine, and various central Asian countries covered by the agreement, is a sweet deal for AHRO shareholders. The USPTO approval, alongside the Phase I-II clinical trialing campaign, adds serious weight to the recent success of preclinical study work completed in conjunction with UCLA and Cedars-Sinai, set to be published in the respective scientific journals (later this year by UCLA and in early 2013 by Cedars-Sinai). The CardioNova deal alone should result in impressive quarterly royalties on net sales over the full lifespan of the IP in that massive market and the global impact of a true statin alternative that also actually gets the job done safely should be enough to pique the interest of potential investors.
This technology also has abundant potential to strike out into new territory, with delipidization of subcutaneous fat being a primary target the company has developed IP for. This function has already been identified by research at top U.S. academic institutions in one of the compounds AHRO has determined to be effective and the potential for burning fat via localized transdermal delivery has, to say the least, exciting profit potential. It is important to stress the overall viability of delipidization and its effect on health and well-being. Given the safety of the compound and its effectiveness, we could be looking at the emergence of new general indication for delimiting lipid buildup throughout the body’s vast network of small peripheral vessels.
Presentations at the recent 2012 Aegis Capital Healthcare Conference (Sept 28) and Rodman & Renshaw 14th Annual Healthcare Conference (Sept 11), have left a lasting impression on the sector, with the incredible near-term potential of the leading AHRO-001 compound, the UCLA study data, and the company’s strong development pipeline all making a significant impact. The company is poised to validate the extant, very encouraging preclinical data with human clinical trials. The compound potential reaches across entire market segments and the absence of negative toxicological effects in the preclinical work accentuates the historically validated safety of this compound class in humans. AHRO-001 should be in Phase I by Q4 2012 and early next year we should see AHRO meeting again with FDA, as they did back in 2011, to clear the way for Phase II work and a U.S. IND filing.
For more information on this exciting young biotech firm, please visit the company’s website located at: www.AtheroNova.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Loans4less.com, Inc. (LFLS) Leads Industry Transformation
Even though the mortgage loan industry as a whole has gone through what is arguably the single biggest setback in its history, with an associated public relations disaster that will remain in the public’s collective mind indefinitely, it has also resulted in a new day for the industry and a better way of doing business. Led by companies like Loans4Less, old-fashioned values are being coupled with the very newest technologies, offering consumers transparency, a sense of confidence, and ease-of-process that is transforming the mortgage loan experience.
With home sales on the rise, it’s a timely and much needed change. Although housing is only one part of the economy, increased home sales encourage increased home prices, supporting the net worth and overall confidence of the public, which in turn can fuel economic activity in other areas. Anything that makes the home buying process more efficient and attractive represents a welcome foundational strength.
Loans4Less was building such a business before the true value of such an orientation was so widely recognized. The company is an online mortgage broker that uses state-of-the-art web and information technologies to ensure efficiencies, but has gone to the greatest lengths to ensure that it is all based upon the most fundamental of positive business and human relation values. It prides itself in maintaining an unblemished consumer service reputation, with an A+ Better Business Bureau record. Although it is committed to offering the lowest rates and closing costs possible, the company strictly avoids things like misleading teaser rates or hidden fees and costs that are still found in the industry.
The company has dedicated itself to addressing the industry’s dominating need for honesty, transparency, and efficiency, and has developed an online presence that clearly reflects that philosophy.
For additional information, visit the company’s website at www.Loans4Less.com
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
With home sales on the rise, it’s a timely and much needed change. Although housing is only one part of the economy, increased home sales encourage increased home prices, supporting the net worth and overall confidence of the public, which in turn can fuel economic activity in other areas. Anything that makes the home buying process more efficient and attractive represents a welcome foundational strength.
Loans4Less was building such a business before the true value of such an orientation was so widely recognized. The company is an online mortgage broker that uses state-of-the-art web and information technologies to ensure efficiencies, but has gone to the greatest lengths to ensure that it is all based upon the most fundamental of positive business and human relation values. It prides itself in maintaining an unblemished consumer service reputation, with an A+ Better Business Bureau record. Although it is committed to offering the lowest rates and closing costs possible, the company strictly avoids things like misleading teaser rates or hidden fees and costs that are still found in the industry.
The company has dedicated itself to addressing the industry’s dominating need for honesty, transparency, and efficiency, and has developed an online presence that clearly reflects that philosophy.
For additional information, visit the company’s website at www.Loans4Less.com
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Teletouch Communications, Inc. (TLLE) Continues to Expand Its Role as Critical Link between Electronics Suppliers and the Marketplace
Teletouch Communications is rapidly transitioning itself into an electronics distribution market leader, and recently announced the signing of their first direct handset manufacturing distribution agreement with TCT Mobile, one of the largest consumer manufacturing companies in the world, expected to generate several million dollars top line. TCT is the maker of the Alcatel OneTouch brand of cellular handsets. Teletouch has also penned at least a dozen other cellular equipment and accessory distribution agreements to support their wholesale business growth strategy.
PCI, the company’s wholly owned subsidiary, continues to expand its extensive range of product offerings under the Teletouch and Hawk brand names, including, but not limited to, the following:
• Cell Phones & Smart Phones, including iPhones
• Docking Stations
• Mobile Communication Accessories
• Mobile Broadband Connectivity
• Bluetooth
• Memory Cards
• Chargers & Batteries
• Tablets, Netbooks, iPads & Accessories
• Signal Boosting Equipment
• eReaders
PCI Wholesale has been a market leader in the cellular and automotive accessory and entertainment businesseses for years, and also provides the training and support needed for its dealer customers to rapidly expand into new areas of mobile technology.
• Car Audio & Security
• Auto & Truck Accessories
• Marine Electronics
• Mobile Video
• GPS & Navigation
• Public Safety Equipment
• Collision Avoidance Systems
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
PCI, the company’s wholly owned subsidiary, continues to expand its extensive range of product offerings under the Teletouch and Hawk brand names, including, but not limited to, the following:
• Cell Phones & Smart Phones, including iPhones
• Docking Stations
• Mobile Communication Accessories
• Mobile Broadband Connectivity
• Bluetooth
• Memory Cards
• Chargers & Batteries
• Tablets, Netbooks, iPads & Accessories
• Signal Boosting Equipment
• eReaders
PCI Wholesale has been a market leader in the cellular and automotive accessory and entertainment businesseses for years, and also provides the training and support needed for its dealer customers to rapidly expand into new areas of mobile technology.
• Car Audio & Security
• Auto & Truck Accessories
• Marine Electronics
• Mobile Video
• GPS & Navigation
• Public Safety Equipment
• Collision Avoidance Systems
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
